Dr Marco Herold-Lab Team

Dr Marco Herold-Lab Team

In addition to our research in haematopoiesis and cancer, my laboratory is responsible for setting up new genome editing technology within the Institute. This is being used for the production of new disease models as well as a whole genome screening in vivo.


Margs Brennan, Postdoctoral Fellow, BSc (Hons) Melbourne

Project: Haematopoietic stem cell regulation/ Targeting MCL-1 in cancer.

Key publication: Brennan MS, Chang C, Tai L, Lessene G, Strasser A, Dewson G, Kelly GL, Herold MJ. Humanized MCL-1 mice enable accurate pre-clinical evaluation of MCL-1 inhibitors destined for clinical use. Blood. 2018 Oct 11;132(15):1573-1583. doi: 10.1182/blood-2018-06-859405. PMID: 30139826


Lahiru Gangoda, Postdoctoral Fellow, BSc(Hons) PhD Melbourne 

Project: Understand the role of the BCL-2 pro-survival protein A1/Bfl-1 in cancer and inflammation.

Key publication: Tan L, Sandrock I, Odak I, Aizenbud Y, Wilharm A, Barros-Martins J, Tabib Y, Borchers A, Amado T, Gangoda L, Herold MJ, Schmidt-Supprian M, Kisielow J, Silva-Santos B, Koenecke C, Hovav AH, Krebs C, Prinz I, Ravens S. Single-Cell Transcriptomics Identifies the Adaptation of Scart1+ Vγ6+ T Cells to Skin Residency as Activated Effector Cells. Cell Rep. 2019 Jun 18;27(12):3657-3671.e4. doi: 10.1016/j.celrep.2019.05.064 PMID: 31216482


Andrew Kueh, Postdoctoral Fellow, BSc(Hons) MB BS PhD Melbourne

Project: Development of new pre-clinical models and advanced CRISPR genome editing and diagnostic tools. 

Key publicaiton: Kueh AJ, Pal M, Tai L, Liao Y, Smyth GK, Shi W, Herold MJ. An update on using CRISPR/Cas9 in the one-cell stage mouse embryo for generating complex mutant alleles. Cell Death Differ. 2017 Jul 28. doi: 10.1038/cdd.2017.122. PMID: 28753205


Martin Pal, Postdoctoral Fellow, PhD Cologne

Project: Development of new in vivo CRISPR screening techniques

Key publication: Lionnard L, Duc P, Brennan MS, Kueh AJ, Pal M, Guardia F, Mojsa B, Damiano MA, Mora S, Lassot I, Ravichandran R, Cochet C, Aouacheria A, Potts PR, Herold MJ, Desagher S, Kucharczak J. TRIM17 and TRIM28 antagonistically regulate the ubiquitination and anti-apoptotic activity of BCL2A1. Cell Death Differ. 2018 Jul 24. doi: 10.1038/s41418-018-0169-5. PMID: 30042493


Yexuan Deng, PhD student Nanjing

Project: Finding new cancer driving genes using advanced CRISPR technologies in vivo


Erin Lawrence, PhD Student, BSc(Hons) Melbourne

Project: Elucidating the role of mutant DNMT3a in diverse disease settings


Maggie Potts, PhD Student, BSc(Hons) Melbourne 

Project: Identification of tumour promoting mutations using CRISPR screening in vivo


Lin Tai, Lab Manager and Senior Research Assistant, BAppSc Swinburne MSc La Trobe

Super Content: 
Three researchers standing outside a building

Researchers have genetically engineered a laboratory model for testing the effectiveness of new anti-cancer drugs called MCL-1 inhibitors.